A case of hepatitis B reactivation due to the hepatitis B virus escape mutant in a patient undergoing chemotherapy

Virologica Sinica

Volumn 27, Issue 6, 2012, Pages 369-372

  Wu, Chunchen ^a   Shi, Hui ^a   Wang, Yun ^a   Lu, Mengji ^a,b,c   Xu, Yang ^b   Chen, Xinwen ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Escape mutant; Hepatitis B reactivation; Lamivudine; Malignancy

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; LAMIVUDINE; LIVER ENZYME; VIRUS DNA;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CASE REPORT; CAUSE OF DEATH; FULMINANT HEPATIC FAILURE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPERTRANSAMINASEMIA; LIVER CIRRHOSIS; MALE; MORBIDITY; MORTALITY; NONHUMAN; VIRUS GENE; VIRUS MUTANT; VIRUS REACTIVATION;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNE EVASION; LAMIVUDINE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION, MISSENSE;

HEPATITIS B VIRUS;

EID: 84875229587     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-012-3284-3     Document Type: Article

References (15)

1. Dienstag J L, Schiff E R, Wright T L, et al. 1999. Lamivudine as initial treatment for chronic hepatitis b in the united states. N Engl J Med, 341(17): 1256-1263. (Pubitemid 29489740)
2. Ferreira R, Carvalheiro J, Torres J, et al. 2012. Fatal hepatitis b reactivation treated with entecavir in an isolated anti-hbs positive lymphoma patient: A case report and literature review. Saudi J Gastroenterol, 18(4): 277-281.
3. Fukushima N, Mizuta T, Tanaka M, et al. 2009. Retrospective and prospective studies of hepatitis b virus reactivation in malignant lymphoma with occult hbv carrier. Ann Oncol, 20(12): 2013-2017.
4. Kim I K, Kim B G, Kim W, et al. 2012. Clinical prediction of failure of lamivudine prophylaxis for patients with hepatitis b infection undergoing cytotoxic chemotherapy for malignancy. Antimicrob Agents Chemother. 56(11): 5511-5519.
5. Kondili L A, Osman H, Mutimer D. 2004. The use of lamivudine for patients with acute hepatitis b (a series of cases). J Viral Hepat, 11(5): 427-431. (Pubitemid 39336223)
6. Lai C L, Chien R N, Leung N W, et al. 1998. A one-year trial of lamivudine for chronic hepatitis b. Asia hepatitis lamivudine study group. N Engl J Med, 339(2): 61-68. (Pubitemid 28304879)
7. Lee I C, Huang Y H, Chu C J, et al. 2010. Hepatitis b virus reactivation after 23 months of rituximab-based chemotherapy in an hbsag-negative, anti-hbs-positive patient with follicular lymphoma. J Chin Med Assoc, 73(3): 156-160.
8. Lu M, Lorentz T. 2003. De novo infection in a renal transplant recipient caused by novel mutants of hepatitis b virus despite the presence of protective anti-hepatitis b surface antibody. J Infect Dis, 187(8): 1323-1326. (Pubitemid 36438974)
9. Matsue K, Kimura S, Takanashi Y, et al. 2010. Reactivation of hepatitis b virus after rituximab-containing treatment in patients with cd20-positive b-cell lymphoma. Cancer, 116(20): 4769-4776.
10. Miyake Y, Iwasaki Y, Takaki A, et al. 2008. Lamivudine treatment improves the prognosis of fulminant hepatitis b. Intern Med, 47(14): 1293-1299.
11. Norder H, Couroucé A M, Coursaget P, et al. 2004. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology, 47(6):289-309. (Pubitemid 39541275)
12. Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, et al. 2004. Lamivudine treatment for acute severe hepatitis b: A pilot study. Liver Int, 24(6): 547-551. (Pubitemid 40028605)
13. Tillmann H L, Hadem J, Leifeld L, et al. 2006. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis b, a multicenter experience. J Viral Hepat, 13(4): 256-263.
14. Yeo W, Chan T C, Leung N W, et al. 2009. Hepatitis b virus reactivation in lymphoma patients with prior resolved hepatitis b undergoing anticancer therapy with or without rituximab. J Clin Oncol, 27(4): 605-611.
15. Yuen M F, Sablon E, Hui C K, et al. 2001. Factors associated with hepatitis b virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology, 34(4 Pt 1): 785-791. (Pubitemid 32928004)